Promising results from the first clinical trials of globin gene transfer to treat beta-thalassemias-inherited forms of anemia-have eliminated the need for blood transfusions in some individuals. Enhancing current gene therapy strategies and applying new gene editing tools to correct beta-globin deficiencies and to reactivate fetal hemoglobin production are among the exciting new advances being pursued in the search for a cure for severe globin disorders, as described in Human Gene Therapy. The article is available free for download on the Human Gene Therapy website until June 5, 2016.
↧